Angion Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

December 21, 2022

https://www.globenewswire.com/news-release/2022/12/22/2578302/0/en/Angion-Receives-Nasdaq-Notice-Regarding-Minimum-Bid-Price-Requirements.html

UNIONDALE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) — Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced that on December 15, 2022, it received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying Angion that for the last 30 consecutive business days the bid price of Angion’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1).

Read more at globenewswire.com

Related news for (ANGN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.